Ad Code: Verzenio - Display Banners P2P - FEB - 196552

Routine screening for patient-reported outcomes may improve access to supportive care services among long-term metastatic breast cancer survivors.

Genomic profiling in the FLEX trial predicted chemotherapy response in HR+, HER2- breast cancer, which could enable tailored treatment plans.

Justin Balko, PharmD, PhD, reviews his session from SABCS 2024 where he discussed the challenges and advancements in immunotherapy for early-stage triple-negative breast cancer (TNBC). Additionally, he discusses the importance of identifying predictive biomarkers to optimize treatment and improve patient quality of life.

Physician’s Weekly spoke with Dr. Otsubo and Dr. Hara about their research and how they anticipate the SDB kit will be applied in clinical settings.

Justin Balko, PharmD, PhD, recently joined Dr. Priyanka Sharma and Dr. Roberto Salgado at the 2024 San Antonio Breast Cancer Symposium to discuss immune biomarkers, including tumor-infiltrating lymphocytes, and their roles.

Dr. Marla Lipsyc-Sharf reviews her recent session at the 2024 SABCS meeting, discussing biopsy approaches and treatment sequencing in metastatic breast cancer.

Oncologist Marla Lipsyc-Sharf, MD, and colleagues will discuss treatment considerations in metastatic ER+ breast cancer at the 2024 SABCS meeting.

This roundup includes a selection of abstracts on early and metastatic breast cancer presented at the 2024 San Antonio Breast Cancer Symposium.

Will you be attending “Case Based Clinical Approach to ER Positive Metastatic Breast Cancer” on Wednesday, December 11?